
Lorna Rodriguez-Rodriguez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10497402/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer. International Journal of Gynecological Cancer, 2022, 32, 1032-1038.	2.5	4
2	Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer. Case Reports in Oncology, 2021, 14, 931-937.	0.7	8
3	CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3. Frontiers in Oncology, 2020, 10, 589601.	2.8	39
4	Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecologic Oncology, 2018, 150, 478-486.	1.4	27
5	Impact of body mass index on ovarian cancer survival varies by stage. British Journal of Cancer, 2017, 117, 282-289.	6.4	25
6	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. International Journal of Molecular Sciences, 2016, 17, 2113.	4.1	165
7	Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. Clinical Cancer Research, 2016, 22, 5909-5914.	7.0	78
8	Precision targeted therapy of ovarian cancer. Journal of Controlled Release, 2016, 243, 250-268.	9.9	59
9	Role of Biomarkers in the Development of PARP Inhibitors. Biomarkers in Cancer, 2016, 8s1, BIC.S36679.	3.6	57
10	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. Biomarkers in Cancer, 2016, 8s1, BIC.S34417.	3.6	27
11	Precision Medicine: Implications for Science and Practice. Journal of the American College of Surgeons, 2016, 223, 433-439e1.	0.5	6
12	Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index. JAMA Oncology, 2015, 1, 737.	7.1	38
13	CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination. Oncotarget, 2015, 6, 26308-26321.	1.8	42
14	Tumor-Targeted Responsive Nanoparticle-Based Systems for Magnetic Resonance Imaging and Therapy. Pharmaceutical Research, 2014, 31, 3487-3502.	3.5	43
15	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
16	Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Advanced Drug Delivery Reviews, 2013, 65, 1880-1895.	13.7	133
17	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
18	Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug. Clinical Cancer Research, 2013, 19, 6193-6204.	7.0	149

Lorna Rodriguez-Rodriguez

#	Article	IF	CITATIONS
19	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169
20	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
21	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International Journal of Epidemiology, 2013, 42, 579-589.	1.9	146
22	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
23	Identification of Function for CD44 Intracytoplasmic Domain (CD44-ICD). Journal of Biological Chemistry, 2012, 287, 18995-19007.	3.4	101
24	Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine, 2012, 7, 185-197.	3.3	43
25	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. PLoS ONE, 2011, 6, e24987.	2.5	48
26	Healthy eating index and ovarian cancer risk. Cancer Causes and Control, 2011, 22, 563-571.	1.8	39
27	Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Women's Health, 2011, 11, 40.	2.0	71
28	Multifunctional Tumor-Targeted Polymer-Peptide-Drug Delivery System for Treatment of Primary and Metastatic Cancers. Pharmaceutical Research, 2010, 27, 2296-2306.	3.5	47
29	Tumor Necrosis Factor-α Differentially Modulates CD44 Expression in Ovarian Cancer Cells. Molecular Cancer Research, 2006, 4, 511-520.	3.4	30
30	The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer. Cancer Research, 2005, 65, 6660-6667.	0.9	209